Table 2.

Baseline clinical details of participants

Total sample (N = 29)	Escitalopram (N = 12)	Placebo (N = 17)	Significance
ASD
Full: 27	N = 12	N = 15
Partial: 2	N = 0	N = 2	p = 0.39
Any MINI disorder
Yes: 19	N = 7	N = 12
No: 10	N = 5	N = 5	p = 0.50
CAPS PTSD
Yes: 15	N = 4	N = 11
No: 14	N = 8	N = 6	p = 0.09
CAPS (mean ± SD)
55.10 ± 23.50	45.33 ± 21.43	62.00 ± 22.98	p = 0.06
CGI-S (mean ± SD)
3.24 ± 0.87	3.08 ± 0.10	3.35 ± 0.79	p = 0.35
MADRS (mean ± SD)
14.79 ± 9.56	11.92 ± 9.42	16.82 ± 9.40	p = 0.05
VAS-D (mean ± SD)
4.45 ± 2.65	3.75 ± 2.60	4.94 ± 2.66	p = 0.24
VAS-A (mean ± SD)
5.22 ± 2.16	5.33 ± 2.19	5.15 ± 2.21	p = 0.82
SDS (mean ± SD)
12.10 ± 7.65	8.83 ± 6.46	14.41 ± 7.75	p = 0.05

CAPS: Clinician Administered PTSD Scale; CGI-S: Clinical Global Impressions Scale- severity; MADRS: MINI: MINI International Neuropsychiatric Interview; Montgomery Asberg Depression Rating Scale; SD: standard deviation; SDS: Sheehan Disability Scale; VAS-D: Visual Analogue Scale-Depression; VAS-A: Visual Analogue Scale- Anxiety.

Note: numbers may not add up to 100% due to missing data.